Versant gambles $20 million on a UCSD spinout focused on NASH and fibrosis
Back in the spring of 2015, Jeffrey Stafford helped set up a deal with Celgene to acquire the drug discovery platform he helped create at San Diego-based Quanticel for up to $485 million, and went along to help shepherd the next stage as an executive at the subsidiary.
Now, he and his former backers at Versant have joined forces again to launch a new preclinical startup focused on the hot R&D field of NASH and fibrosis. And he’s joined by longtime colleague Jim Veal, who is the new CSO at the fledgling Jecure Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.